Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia

S. Kurosawa, T. Yamaguchi, Takehiko Mori, H. Kanamori, Y. Onishi, N. Emi, S. Fujisawa, A. Kohno, C. Nakaseko, B. Saito, T. Kondo, M. Hino, Y. Nawa, S. Kato, A. Hashimoto, T. Fukuda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

When discussing treatment options for patients with acute leukemia, it is important to acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or chemotherapy on quality of life (QOL). We performed a cross-sectional questionnaire study that administered SF-36, FACT-Leukemia and EuroQOL5D to 524 acute leukemia survivors, to compare patient-reported QOL between chemotherapy and allo-HCT, and to elucidate predictors of QOL. Patients who received chemotherapy alone had a better physical QOL than those who received allo-HCT. On the other hand, the allo-HCT group reported a better mental QOL. In the comparison of QOL in the allo-HCT patients according to the presence of GVHD at survey, patients who had GVHD symptoms experienced statistically and clinically significantly worse QOL than those who did not. In the allo-HCT patients without GVHD, the physical QOL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QOL than the chemotherapy patients. GVHD and immunosuppressive drugs at survey were strongly associated with worse QOL after allo-HCT. In the chemotherapy group, a shorter time between treatment completion and survey was significantly associated with worse QOL. Further evaluation of QOL by a longitudinal assessment with quantitative and qualitative analyses are warranted.

Original languageEnglish
Pages (from-to)1241-1249
Number of pages9
JournalBone Marrow Transplantation
Volume50
Issue number9
DOIs
Publication statusPublished - 2015 Sep 4

Fingerprint

Cell Transplantation
Leukemia
Quality of Life
Drug Therapy
Immunosuppressive Agents
Survivors
Cross-Sectional Studies

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. / Kurosawa, S.; Yamaguchi, T.; Mori, Takehiko; Kanamori, H.; Onishi, Y.; Emi, N.; Fujisawa, S.; Kohno, A.; Nakaseko, C.; Saito, B.; Kondo, T.; Hino, M.; Nawa, Y.; Kato, S.; Hashimoto, A.; Fukuda, T.

In: Bone Marrow Transplantation, Vol. 50, No. 9, 04.09.2015, p. 1241-1249.

Research output: Contribution to journalArticle

Kurosawa, S, Yamaguchi, T, Mori, T, Kanamori, H, Onishi, Y, Emi, N, Fujisawa, S, Kohno, A, Nakaseko, C, Saito, B, Kondo, T, Hino, M, Nawa, Y, Kato, S, Hashimoto, A & Fukuda, T 2015, 'Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia', Bone Marrow Transplantation, vol. 50, no. 9, pp. 1241-1249. https://doi.org/10.1038/bmt.2015.137
Kurosawa, S. ; Yamaguchi, T. ; Mori, Takehiko ; Kanamori, H. ; Onishi, Y. ; Emi, N. ; Fujisawa, S. ; Kohno, A. ; Nakaseko, C. ; Saito, B. ; Kondo, T. ; Hino, M. ; Nawa, Y. ; Kato, S. ; Hashimoto, A. ; Fukuda, T. / Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 9. pp. 1241-1249.
@article{ceecaad5d7cf44dc9cc29a2042435181,
title = "Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia",
abstract = "When discussing treatment options for patients with acute leukemia, it is important to acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or chemotherapy on quality of life (QOL). We performed a cross-sectional questionnaire study that administered SF-36, FACT-Leukemia and EuroQOL5D to 524 acute leukemia survivors, to compare patient-reported QOL between chemotherapy and allo-HCT, and to elucidate predictors of QOL. Patients who received chemotherapy alone had a better physical QOL than those who received allo-HCT. On the other hand, the allo-HCT group reported a better mental QOL. In the comparison of QOL in the allo-HCT patients according to the presence of GVHD at survey, patients who had GVHD symptoms experienced statistically and clinically significantly worse QOL than those who did not. In the allo-HCT patients without GVHD, the physical QOL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QOL than the chemotherapy patients. GVHD and immunosuppressive drugs at survey were strongly associated with worse QOL after allo-HCT. In the chemotherapy group, a shorter time between treatment completion and survey was significantly associated with worse QOL. Further evaluation of QOL by a longitudinal assessment with quantitative and qualitative analyses are warranted.",
author = "S. Kurosawa and T. Yamaguchi and Takehiko Mori and H. Kanamori and Y. Onishi and N. Emi and S. Fujisawa and A. Kohno and C. Nakaseko and B. Saito and T. Kondo and M. Hino and Y. Nawa and S. Kato and A. Hashimoto and T. Fukuda",
year = "2015",
month = "9",
day = "4",
doi = "10.1038/bmt.2015.137",
language = "English",
volume = "50",
pages = "1241--1249",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia

AU - Kurosawa, S.

AU - Yamaguchi, T.

AU - Mori, Takehiko

AU - Kanamori, H.

AU - Onishi, Y.

AU - Emi, N.

AU - Fujisawa, S.

AU - Kohno, A.

AU - Nakaseko, C.

AU - Saito, B.

AU - Kondo, T.

AU - Hino, M.

AU - Nawa, Y.

AU - Kato, S.

AU - Hashimoto, A.

AU - Fukuda, T.

PY - 2015/9/4

Y1 - 2015/9/4

N2 - When discussing treatment options for patients with acute leukemia, it is important to acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or chemotherapy on quality of life (QOL). We performed a cross-sectional questionnaire study that administered SF-36, FACT-Leukemia and EuroQOL5D to 524 acute leukemia survivors, to compare patient-reported QOL between chemotherapy and allo-HCT, and to elucidate predictors of QOL. Patients who received chemotherapy alone had a better physical QOL than those who received allo-HCT. On the other hand, the allo-HCT group reported a better mental QOL. In the comparison of QOL in the allo-HCT patients according to the presence of GVHD at survey, patients who had GVHD symptoms experienced statistically and clinically significantly worse QOL than those who did not. In the allo-HCT patients without GVHD, the physical QOL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QOL than the chemotherapy patients. GVHD and immunosuppressive drugs at survey were strongly associated with worse QOL after allo-HCT. In the chemotherapy group, a shorter time between treatment completion and survey was significantly associated with worse QOL. Further evaluation of QOL by a longitudinal assessment with quantitative and qualitative analyses are warranted.

AB - When discussing treatment options for patients with acute leukemia, it is important to acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or chemotherapy on quality of life (QOL). We performed a cross-sectional questionnaire study that administered SF-36, FACT-Leukemia and EuroQOL5D to 524 acute leukemia survivors, to compare patient-reported QOL between chemotherapy and allo-HCT, and to elucidate predictors of QOL. Patients who received chemotherapy alone had a better physical QOL than those who received allo-HCT. On the other hand, the allo-HCT group reported a better mental QOL. In the comparison of QOL in the allo-HCT patients according to the presence of GVHD at survey, patients who had GVHD symptoms experienced statistically and clinically significantly worse QOL than those who did not. In the allo-HCT patients without GVHD, the physical QOL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QOL than the chemotherapy patients. GVHD and immunosuppressive drugs at survey were strongly associated with worse QOL after allo-HCT. In the chemotherapy group, a shorter time between treatment completion and survey was significantly associated with worse QOL. Further evaluation of QOL by a longitudinal assessment with quantitative and qualitative analyses are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84940896020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940896020&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.137

DO - 10.1038/bmt.2015.137

M3 - Article

VL - 50

SP - 1241

EP - 1249

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -